Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

- Oral presentation of top-line IMPULSE data including invited expert discussion - Poster presentation of new data on lefitolimod as modulator of the tumor microenvironment alone and in combination with immune checkpoint inhibitors in pre-clinical tumor models [more]

The Executive Board of biopharmaceutical company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today signed a binding term sheet that defines the framework for the collaboration between MOLOGEN and iPharma. iPharma is a China-based drug development company and a joint venture between the Chinese investor I-Bridge Capital and BiolineRx Ltd., a company... [more]

Annual Report 2016
Download PDF

 Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF